By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
McKesson's FY26 results were strong with 18% EPS growth, driven by oncology and specialty pharmacy expansion. The company's plan to spin off Medical-Surgical Solutions and focus on higher-margin businesses is seen as a positive move, but there are concerns about the CFO transition and potential margin compression from the Inflation Reduction Act.
Risk: CFO transition and potential margin compression from the Inflation Reduction Act
Opportunity: Spin-off of Medical-Surgical Solutions to focus on higher-margin businesses
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Image source: The Motley Fool.
Thursday, May 7, 2026 at 4:30 p.m. ET
- Chief Executive Officer — Brian Tyler
- Chief Financial Officer — Britt Vitalone
Need a quote from a Motley Fool analyst? Email [email protected]
Brian Tyler: Thank you, Jeni. Good afternoon, and thanks, everyone, for joining McKesson's fiscal fourth quarter earnings call. Earlier today, we reported a good fourth quarter that caps a year of strong performance. In our fiscal 2026, we grew adjusted earnings per diluted share by 18%, driven by momentum across our strategic growth platforms. Our operating cash flow of $6.2 billion was strong and exceeded our plans. We returned over -- we returned $5.1 billion to shareholders. Fiscal '26 was another great year of execution and disciplined portfolio actions that sharpened our focus and drove continued operating momentum. At the beginning of the year, we added Core Ventures and PRISM Vision to our oncology and our multispecialty platforms.
Both businesses have been onboarded seamlessly, delivering strong growth momentum while expanding high-quality care in the community setting. One year ago, we announced the plan to separate our Medical-Surgical Solutions segment into an independent company. Since then, we've made significant progress towards that objective. We put transition service agreements in place, executed on financing transactions and signed an agreement to welcome Apollo as a minority interest investor while advancing the separation readiness of the business itself. As we continue to execute towards our planned separation, we're confident that it will unlock shareholder value and create strategic clarity for both organizations.
In January, we completed our exit from Norway, continuing our disciplined approach to portfolio optimization and fulfilling our commitment to fully exit the European business. Operationally, we made moves to better align our organizational structure to our strategy. We introduced new reporting segments, allowing increased transparency to our growth areas and better aligning reporting with how we operate the business and how we allocate capital. Our execution on these strategic initiatives drove the strong results we delivered in fiscal '26 and position us well for fiscal '27. Looking ahead, we anticipate adjusted earnings per diluted share to be in the range of $43.80 to $44.60 in fiscal '27.
With a strategically focused portfolio, a strong balance sheet and a clear operating model, we are well positioned to deliver long-term value for shareholders while performing the critical role we play across the health care value chain. Now let me share with you how our company priorities are shaping the future of McKesson. I'll start with our focus on people and culture, which remains the key enabler of everything we do. We're operating in a complex and rapidly evolving environment and defining our future requires us to continue evolving how we lead while being grounded in our values and our mission.
We embed this into our culture with our I2CARE principles, which represent our values, integrity, inclusion, customer-first, respect and excellence. And through LEADRx, our leadership principles. Together, this is our leadership prescription framework. It reinforces accountability, trust and focus on serving our customers. LEADRx provides a common standard to guide bold decision-making, deliver results that matter with speed and to build the teams of tomorrow. I am always inspired by Team McKesson and how they demonstrate these leadership behaviors. Today, I want to recognize two individuals who have been exceptional partners to me and to our leadership team. During the quarter, we announced the planned retirement of Britt.
Over the course of his tenure, he's played a critical role in strengthening McKesson's financial foundation, advancing our capital deployment framework and positioning the company for long-term sustainable growth. His leadership has been marked by discipline, clarity and an unwavering focus on value creation for shareholders. Britt has helped build a strong deep finance organization that will continue to serve the company well into the future. I would be remiss if I didn't note that during Britt's tenure as CFO, we've delivered over 500% increase in shareholder returns. That's over 20% annual growth rate. Thank you, Britt. Additionally, we are announcing changes to our Board.
Don Knauss will complete his service on our Board prior to the 2026 Annual Stockholder Meeting in July, consistent with our outside director age guidelines. I want to thank Don for his steady leadership and significant contributions as the Independent Chair of our Board. Effective May 1, I was elected Chairman of our Board to serve alongside Dominic Caruso, who has 7 years of experience on McKesson's Board. He will serve as the Lead Independent Director, ensuring continued ongoing strong independent oversight. I'd like to now discuss our strategic pillars. Let me start with oncology and multispecialty platforms.
We continue to see strong growth in specialty medications, and we're leveraging our differentiated portfolio of solutions to improve access, support providers in the community and empower biopharma customers with valuable data and insights. We are pleased to see continued expansion of these platforms. For the U.S. Oncology Network, it's been a remarkable year of growth. We added more than 570 providers in fiscal '26, the largest net increase since 2010. In April, we further expanded our footprint with the addition of Cancer Care Northwest with clinic locations across Washington and Idaho. We continue to leverage our capabilities and onboard Core Ventures onto our platform.
Ontada, our data and insights business, for example, is now incorporating in-office dispensing data from Florida Cancer Specialists and Research Institute. This expands the data we provide to biopharma customers to better assess adoption and performance trends across the broader community oncology landscape. As we scale the platform, we're embedding automation and AI to improve workflow and enhance the patient experience. Within the U.S. Oncology Network, Ambient Scribe technology is now used by more than 1,900 providers. This allows them to spend more time with patients and less time on documentation, allowing them to do the jobs they trained for.
These capabilities illustrate how we're using data technology and scale to meaningfully improve our physicians' productivity and dedicate more time to care delivery. Within our retina and ophthalmology platform, PRISM Vision increased providers by approximately 20% over the past year and welcomed two new practices, Spokane Eye Clinic and more recently in May, the Retina Macula Institute, extending its footprint beyond the Mid-Atlantic region. Let's move on to our biopharma services platform. Our fiscal fourth quarter is typically the busiest time of the year as we support patients with their annual verifications. This year, we delivered the most successful season to date, supporting a record number of 3.4 million patients in their journey to access the medicines they need.
We achieved this through strong execution, disciplined planning and continued productivity investments, including the application of technology and automation. As a result, each full-time employee supported 120 more patients this season compared to last year. We're pleased with the continued business momentum, supported by a differentiated and scaled network. We're digitally connected to over 50,000 pharmacies and more than 1 million providers, and we support over 650 biopharma brands, representing most therapeutic areas. Over the past year, we helped patients save approximately $10 billion on brand and specialty medications, the majority of which were for non-GLP-1 drugs.
We helped to prevent an estimated 12 million prescriptions from being abandoned due to affordability challenges, and we enabled patients to access their medicines more than 135 million times. Building on this scale and continued momentum, we consistently reinvest into the business to advance our strategic focus on technology-enabled services. These investments focus on enhancing product functionality, improving the customer experience and introducing greater automation. Recently, we launched an industry-first integrated specialty access and affordability solution designed to address the fragmentation that often delays starting a treatment. By connecting benefits verification, prior authorization and affordability support into a single coordinated workflow, this solution helps manufacturers accelerate time to therapy for high-cost, high-touch medications.
This is a powerful example of how we're leveraging our scale and technology to support biopharma customers where access matters most. Turning to North American distribution. We remain focused on operational excellence and long-term sustainability as we continually build a more resilient, scalable distribution platform. Recently, we achieved a key milestone with the successful launch of our new Montreal distribution center. As part of our supply chain of the future initiative, this state-of-the-art facility expands critical capacity and features industry-leading automation, including an advanced storage and retrieval system powered by AI and robots, which raised the standard for precision and performance.
Once fully ramped, this facility will enhance resiliency, improve service reliability across Eastern Canada and reinforce our ability to serve customers and patients with greater speed, consistency and efficiency. Across our supply chains, AI-driven inventory planning capabilities are helping us move from reactive to more technology-enabled real-time decision-making. We implemented an advanced planning system that uses AI to connect and orchestrate end-to-end planning across demand, supply, inventory and operations inside an integrated environment. This transformation enables us to deliver working capital savings and meaningfully contributed to the strong operating cash flow in fiscal 2026.
As we operate a scaled network that distributes approximately 1/3 of pharmaceuticals in North America, we take great pride in protecting the resiliency of our supply chain. In January, a significant winter weather across more than 20 states strained transportation networks. Through early risk monitoring, proactive planning and strong execution, we maintain safe operations and minimize disruptions to our customers and their patients. This is yet another example that underscores the strength and reliability of our operating model and our focus on excellent service. In the past quarter, we successfully navigated the first wave of branded pharmaceutical price changes related to the Inflation Reduction Act.
As expected, there was an impact to revenue growth, but the fundamentals of our business and the strength of our value proposition to manufacturers remain very strong, evidenced by the double-digit adjusted segment operating profit growth in fiscal '26. We continue to manage the business with discipline, ensuring appropriate compensation for the critical services we provide, which position us well for sustained long-term growth. We're operating in a dynamic policy environment. McKesson has a unique role to play, collaborating with policymakers and advocating for changes that advance health care for all. We're confident that our differentiated capabilities will continue to position us to evolve with the market and to enable better outcomes.
Now let me provide a brief update on our portfolio actions. In April, we reached an important milestone in preparing Medical-Surgical Solutions for separation. We completed two financing transactions, a $1 billion senior secured Term Loan A and a $1 billion revolving credit facility. This aids in establishing a stand-alone capital structure for the business, supporting separation readiness and positioning NewCo with financial flexibility as an independent company. We also announced a definitive agreement with Apollo Funds for a $1.25 billion strategic minority investment in Medical-Surgical Solutions, representing approximately 13% minority interest and valuing NewCo at approximately $13 billion of total enterprise value. The transaction is subject to regulatory approvals and customary closing conditions.
We will retain operating control and majority ownership while benefiting from Apollo's experience in supporting complex carve-outs and public market transactions. This is another meaningful step forward as we execute the next phase of the separation and prepare for the planned IPO with a clear focus on maximizing value for shareholders. Let me close with this. McKesson delivered another year of strong operational performance, reflecting the strength of our growth strategy, the value of our differentiated portfolio and our disciplined portfolio management. We enter fiscal '27 from a position of strength with clear momentum across the business. We're well positioned to continue building on that momentum and to deliver sustainable long-term value to our customers, partners and shareholders.
Before I turn the call over to Britt, I want to thank McKesson's employees for their commitment and contributions, which are fundamental to our success. This is also Britt's last earnings call. I want to thank him for 20 years of outstanding leadership and service. As planned, Britt will continue to support the team through the CFO transition, ensuring continuity and stability for the team and operations. He'll also serve as a strategic adviser, providing valuable perspective as we execute our priorities, including the planned separation of the medical business. With that, Britt, I turn it over to you.
Britt Vitalone: Thank you, Brian, and good afternoon. Fiscal 2026 represents another year of exceptional financial performance. We delivered robust growth across our Core strategies while expanding operating leverage through disciplined execution and portfolio actions that create long-term shareholder value. For the full year, consolidated revenues reached $403 billion, a 12% increase. Adjusted operating profit grew 15% to $6.5 billion and adjusted earnings per diluted share increased 18% to $39.11. Excluding the gains from McKesson Ventures investments in fiscal 2025, adjusted earnings per diluted share increased 20%, driven by strong execution across the business and continued strength in our operating fundamentals. Notably, these results exceeded the long-term growth targets that we are reaffirming today.
Today, I'll review our fourth quarter and full year results, followed by our fiscal 2027 outlook. Unless otherwise noted, my comments will refer to our adjusted results. Before turning to our consolidated results, I want to briefly address three items that impacted fourth quar
Four leading AI models discuss this article
"McKesson’s strategic pivot toward high-growth oncology and specialty platforms, combined with disciplined portfolio optimization, creates a sustainable earnings trajectory that justifies a premium valuation despite regulatory scrutiny."
McKesson’s fiscal 2026 results demonstrate a masterclass in capital allocation and operational efficiency. The 18% adjusted EPS growth, underpinned by a 12% revenue increase to $403 billion, confirms that the pivot toward oncology and specialty pharmacy is yielding significant margin expansion. The $13 billion valuation for the Medical-Surgical Solutions carve-out via the Apollo minority stake provides a clear roadmap for unlocking shareholder value through a spin-off. By integrating AI-driven inventory management and Ambient Scribe technology, McKesson is successfully defending its moat against margin compression from the Inflation Reduction Act. The company’s ability to grow despite regulatory headwinds suggests a robust, durable business model.
The heavy reliance on specialty medication growth and biopharma services makes the company highly sensitive to potential future drug pricing legislation or shifts in Medicare reimbursement models that could compress the margins of their oncology network. Furthermore, the complexity of the Medical-Surgical separation may distract management during a critical transition period, potentially masking underlying operational friction.
"McKesson's FY27 EPS guide and MSS spin-off position it for 12-14%+ annual growth, re-rating shares as specialties drive outperformance over peers."
McKesson delivered FY26 blowout with 18% adj EPS growth to $39.11 on 12% revenue rise to $403B, beating long-term targets via oncology network expansion (570+ providers added), biopharma scale (3.4M patients), and AI-driven efficiency yielding $6.2B op cash flow. FY27 guide of $43.80-$44.60 implies 12-14% growth. MSS spin-off (NewCo $13B EV, Apollo $1.25B for 13%) unlocks value, exits low-growth Europe, and refocuses on specialties. Bullish setup for sustained mid-teens EPS amid resilient distribution.
IRA price controls already hit Q4 revenue growth, with further erosion possible in distribution margins (core ~80% of rev), while MSS spin-off risks regulatory delays, execution hiccups, and management distraction amid CFO transition.
"MCK's specialty/oncology growth is real and differentiated, but FY27 guidance deceleration and IRA pricing headwinds make the valuation case dependent on separation execution and whether North American distribution margins can hold."
MCK delivered 18% EPS growth on $403B revenue (+12%), with operating cash flow of $6.2B and $5.1B shareholder returns—operationally solid. The oncology/specialty platforms show real traction (570 net provider adds, record 3.4M patients in biopharma services). But the guidance for FY27 ($43.80–$44.60 EPS) implies only ~12% growth at midpoint, a deceleration from 18%. The Medical-Surgical Solutions separation at $13B valuation (with Apollo taking 13%) signals confidence, but carve-outs are execution minefields. IRA pricing headwinds are acknowledged but downplayed as 'managed with discipline'—this deserves scrutiny on margin sustainability.
The 12% FY27 EPS guidance deceleration, combined with acknowledged IRA pricing pressure and the complexity of separating a $13B business while integrating recent acquisitions, suggests management may be front-loading optimism on specialty platforms while underestimating execution risk.
"McKesson’s cash generation and diversified platforms support long-term value, but the MSS separation and policy headwinds are the key variables determining upside."
McKesson delivered solid 2026 results with 18% adj EPS growth, roughly $6.2B in operating cash flow, and a $5.1B return of capital, while advancing the Medical-Surgical separation and Apollo minority investment. The core thesis is intact: diversified platforms across oncology, biopharma services, and distribution, plus AI-enabled planning, support continued cash flow and a potential value unlock from the split. Yet the upside hinges on execution of the carve-out, regulatory clearances, and IPO timing. Policy headwinds from IRA price changes, plus the loss of European scale, could cap multiple expansion if market conditions worsen or MSS integration stalls.
The main bet rests on a successful MSS separation; if the carve-out stalls or the IPO is delayed, the perceived value could evaporate and the stock could re-rate lower despite strong near-term cash flow.
"The FY27 EPS deceleration reflects a strategic pivot toward higher-margin specialty services rather than a loss of operational momentum."
Claude is right to flag the EPS deceleration, but misses the capital allocation pivot. By exiting lower-margin European distribution and carving out Medical-Surgical, McKesson is essentially trading volume for higher-margin specialty services. The 12% guidance isn't just deceleration; it’s a deliberate shift toward a higher-quality, less-cyclical earnings profile. The real risk isn't the growth rate—it’s whether management can maintain the oncology moat once the IRA’s 'maximum fair price' provisions hit more high-spend specialty drugs.
"CFO transition plus high OCF payout ratio heightens execution vulnerability during MSS spin-off."
Gemini's 'quality shift' defense ignores Grok's CFO transition risk: spinning a $13B MSS unit demands seasoned financial leadership, yet the new CFO inherits peak complexity. With $5.1B returns consuming 82% of $6.2B OCF, there's no cash buffer for oncology provider adds (570 last year) if IRA erodes margins further. This setup risks forced dilution or stalled growth, not durable earnings upgrade.
"MSS spin-off likely *improves* MCK's cash flexibility for specialty investment, not constrains it—if execution succeeds."
Grok's cash flow math is tight but misses a crucial offset: the $13B MSS carve-out removes a low-margin, capital-intensive business from MCK's balance sheet. That frees ~$2-3B in annual capex and working capital—enough to fund oncology expansion without dilution, even if IRA margins compress 50-100 bps. The real CFO test isn't complexity; it's whether the separation *accelerates* specialty growth by removing distribution drag.
"MSS carve-out carries near-term value risk from execution and timing, potentially delaying the value unlock even if cash flow looks solid."
While Grok rightly flags CFO transition and margins, the MSS carve-out introduces execution and timing risk that could sap near-term value. Even if capex is freed, separation costs, potential tax leakage, and an IPO delay could push the value unlock out, keeping multiples tethered to cash flow instead of the implied margin upgrade. A credible, under-promised plan for timing and costs is essential to sustain the bull case.
McKesson's FY26 results were strong with 18% EPS growth, driven by oncology and specialty pharmacy expansion. The company's plan to spin off Medical-Surgical Solutions and focus on higher-margin businesses is seen as a positive move, but there are concerns about the CFO transition and potential margin compression from the Inflation Reduction Act.
Spin-off of Medical-Surgical Solutions to focus on higher-margin businesses
CFO transition and potential margin compression from the Inflation Reduction Act